STOCK TITAN

Fulgent Genetics (FLGT) SEC Filings, Jul-Aug 2025

FLGT NASDAQ

Fulgent Genetics, Inc. filings document operating results, business updates, governance matters, capital-structure activity, and clinical disclosures for a company with laboratory services and therapeutic development operations. Form 8-K reports furnish earnings releases, investor presentation updates, stock repurchase activity, and material-event disclosures tied to the company's business and pipeline.

The company's proxy materials cover board and shareholder voting matters, executive compensation, equity awards, and other governance disclosures. Clinical and regulatory filings include updates related to FID-007 in recurrent or metastatic head and neck squamous cell carcinoma, while broader disclosures address financial performance, risk, and capital allocation.

Rhea-AI Summary

Paul Kim, CFO and Treasurer of Fulgent Genetics, Inc. (FLGT) reported a routine disposition on 08/23/2025 in which 670 shares of common stock were disposed (transaction code F) at a price of $21.77 per share. The filing explains these shares were withheld to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 23, 2023. After the withholding, the reporting person beneficially owned 339,158 shares directly. The Form 4 is signed by Paul Kim on 08/26/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
insider
-
Rhea-AI Summary

Gao Hanlin, Chief Scientific Officer of Fulgent Genetics, Inc. (FLGT), reported a sale of common stock on 08/25/2025 to satisfy tax withholding from vested restricted stock units originally granted on February 23, 2023. The Form 4 shows 548 shares sold at a weighted-average price of $21.5016 (individual sale prices ranged from $21.46 to $21.57). After the sale, the reporting person beneficially owned 959,091 shares. The filing was submitted by attorney-in-fact Paul Kim on 08/26/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
insider
-
Rhea-AI Summary

Form 144 notice for Fulgent Genetics, Inc. (FLGT): An individual identified as Jian Xie proposes to sell 696 shares of the issuer's common stock through Morgan Stanley Smith Barney LLC with an approximate aggregate market value of $14,965.08 and an approximate sale date of 08/25/2025 on NASDAQ. The shares were acquired on 02/23/2023 as restricted stock vesting from Fulgent Genetics as equity compensation; the filer shows total acquired amount of 14,573 shares. The issuer has 30,609,044 shares outstanding. The filer reported three prior sales in the past three months totaling 3,008 shares for gross proceeds of $61,471.47. The form includes the standard representation that the seller is unaware of undisclosed material adverse information.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
other
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.53%
Tags
insider
-
Rhea-AI Summary

Fulgent Genetics (FLGT) Q2-25 10-Q highlights

  • Revenue: $81.8 m, up 15% YoY; 1H-25 revenue $155.3 m (+15%). Precision Diagnostics remains the largest line ($47.3 m, 58%).
  • Gross margin: 42.1% vs 37.3% prior-year as cost discipline in laboratory services offsets mix shift.
  • Operating loss: –$19.7 m (vs –$18.9 m). Operating expenses rose 19% to $54.1 m on higher G&A (+24%) and marketing spend (+43%).
  • Net loss attributable to shareholders: –$19.0 m (EPS –$0.62) vs –$8.7 m (–$0.29). 1H-25 EPS –$0.99.
  • Impairment: $9.9 m write-down of Helio Genomics investment drove other expense; without it, other income was $8.1 m interest.
  • Cash & investments: $777 m (cash + marketable securities) with $87.9 m cash vs $55.1 m YE-24. Long-term securities declined $86 m as durations shortened; total assets $1.2 bn.
  • Operating cash flow: –$34.6 m vs +$11.6 m prior year, due mainly to $33 m federal tax payments and higher receivables.
  • Share activity: Repurchased $13.9 m stock YTD; share count 30.6 m.
  • Customer concentration: One institutional customer accounted for 22% of Q2 revenue and 29% of receivables.
  • Regulatory matters: DOJ CIDs on lab billing and HRSA audit remain open; SEC investigation closed with no action (previous $1 m accrual reversed).

Outlook: Management did not provide forward guidance in the filing. Revenue growth persists but profitability deteriorated due to higher opex and one-time impairment; cash position remains strong.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.86%
Tags
quarterly report
-
Form 8-K
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.86%
Tags
current report
Rhea-AI Summary

Fulgent Genetics (FLGT) filed a Form 4 showing that CFO & Treasurer Paul Kim had 2,743 common shares withheld on 07/26/2025 to cover taxes upon the vesting of RSUs tied to the 2022 Fulgent Pharma merger. The transaction was coded “F,” meaning it was an automatic, non-discretionary share surrender for tax withholding, not an open-market sale. The shares were valued at an implied $18.37 each (company-supplied price).

After the withholding, Kim directly owns 339,828 shares, so his economic exposure fell by <1 %. No derivative securities were exercised or disposed of, and no cash changed hands. Because the disposition is routine and immaterial relative to Kim’s total stake, the filing is largely neutral for investors and does not alter the company’s fundamental outlook.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.46%
Tags
insider
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.46%
Tags
insider
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.46%
Tags
insider
Schedule 13G/A
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.46%
Tags
other

FAQ

How many Fulgent Genetics (FLGT) SEC filings are available on StockTitan?

StockTitan tracks 101 SEC filings for Fulgent Genetics (FLGT), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Fulgent Genetics (FLGT)?

The most recent SEC filing for Fulgent Genetics (FLGT) was filed on November 18, 2026.